Sana Biotechnologyの空売り状況は、投資家がSana Biotechnologyの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Sana Biotechnology (NASDAQ:SANA) 株価情報, 空売り情報

Sana Biotechnology

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.

Sana Biotechnology Inc

SANAI HEALTH IND GROUP CO by SANAI HEALTH IND GROUP CO LTD.

Sanara MedTech Inc

Sanarco Funds Inc

SANATANA RESOURCES NEW by Sanatana Resources Inc.

Sanatana Resources Inc

Barclays analyst Blayne Curtis maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and lowers the price target from $330 to $280.

News

Price Target

Analyst Ratings

NXPI

Barclays Maintains Overweight on NXP Semiconductors, Lowers Price Target to $280

It's Election day! Voters are visiting polling locations and social media mavens are sharing opinions and local reports in megathreads, polls and comments on Reddit Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>).
Here are some notable threads to follow for election <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41631795/reddit-remains-a-favorite-for-wall-street-after-emphatic-beat-and-raise-in-q3">coverage on Reddit.&nbsp;</a>
Polls Open: Subreddit r/politics has over 8.5 million subscribers and features a <a href="https://www.reddit.com/r/politics/comments/1gkefi6/rpolitics_2024_us_elections_live_thread_part_59/">live thread</a> with 59 parts titled, "2024 US Elections Live Thread, Part 59" which contains more than 3,200 comments, voter turnout reports from different locations and live commentary on election developments.&nbsp;
Subreddit r/moderatepolitics has 295,000 members and a <a href="https://www.reddit.com/r/moderatepolitics/">poll titled</a> "Who are you voting for in the 2024 US Presidential Election." At the time of publication, 2,100 Redditors selected Harris, 1,300 selected Trump, 301 selected Other and 842 responded with Not Voting.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/24/10/41612293/reddit-stock-soars-after-strong-q3-results-q4-guidance-above-estimates-dauqs-grow-17-and-more">Reddit Stock Soars After Strong Q3 Results, Q4 Guidance Above Estimates: DAUq&#8217;s Grow 17% And More</a>
Reddit also features local subreddits like r/Pennsylvania, which has <a href="https://www.reddit.com/r/Pennsylvania/comments/1gjutyd/the_election_day_mega_thread/">a thread</a> titled, "The Election Day Mega Thread" where users can find coverage of the crucial swing state and voting guides and polling locations. The thread also provides local polling updates and news with first-hand accounts from voters across the state.&nbsp;
Where To Find Results: FiveThirtyEight, the data journalism outlet, will feature county-by-county data breakdowns as the polling results come in at its r/fivethirtyeight <a href="https://www.reddit.com/r/fivethirtyeight/">subreddit</a>. It also features discussions about polling accuracy and several live election megathreads.&nbsp;&nbsp;
The r/Journalism <a href="https://www.reddit.com/r/Journalism/">subreddit</a> will provide authoritative sources for results, including updates from the Associated Press and major networks, as well as discussions about result reporting methodology.&nbsp;
Reddit&#8217;s election coverage offers a blend of real-time updates and community engagement across various specialized subreddits, though most users recommend keeping multiple sources open for the most complete picture.&nbsp;
RDDT Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Reddit shares ended Tuesday&#8217;s session 12.42% higher at $122.57.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41685913/jpmorgan-to-pay-investors-151-million-after-sec-flags-various-law-violations">JPMorgan To Pay Investors $151 Million After SEC Flags &#8216;Various Law Violations&#8217;</a></li>
</ul>
Photo: Shutterstock

Social Media

Politics

Tech

General

RDDT

Redditors Track Election Night: Must-Watch Threads For Trump Vs. Harris Showdown, Other Races

WIIM

WillScot Holdings shares are trading higher following a report suggesting activist investor TOMS has built a stake in the company and is pushing for a review.

JP Morgan analyst Kevin Yin upgrades Yum China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) from Neutral to Overweight and raises the price target from $35.5 to $60.

Upgrades

YUMC

JP Morgan Upgrades Yum China Holdings to Overweight, Raises Price Target to $60

With the first polling places about to close in what is <a href="https://www.benzinga.com/general/politics/24/11/41748843/trump-holds-edge-in-betting-markets-on-election-day-while-experts-call-tight-race-for-harris">expected to be a neck-and-neck election night</a>, reports from Georgia and Michigan say those two swing states are seeing record-high turnout.
What Happened: Turnout in Philadelphia is also reported to be extremely high, with Reuters reporting turnout as much as 50% higher in some precincts than in 2020. A big win in Philadelphia would go a long way toward delivering Pennsylvania &#8211; the largest and tightest swing state &#8211; to Kamala Harris.
At 4:39 p.m. EDT, Donald Trump wrote on Truth Social: &#8220;A lot of talk about massive CHEATING in Philadelphia. Law Enforcement coming!!!&#8221; 
A Philadelphia police spokesman <a href="https://fortune.com/2024/11/05/donald-trump-claims-cheating-police-philadelphia-pennsylvania/">told Fortune</a> they are &#8220;not aware of anything at this time.&#8221; 
Charlie Kirk of pro-Trump group Turning Point Action wrote earlier on X: &#8220;Turnout is mixed and not where we want it to be. We need more people to vote.&#8221;
Also Read: <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">2024 Election Stakes: Potential Sweeps, Split Outcomes In Congressional, Presidential Races</a>
Politico is <a href="https://www.politico.com/live-updates/2024/11/05/2024-elections-live-coverage-updates-analysis/turnout-high-in-georgia-00187458">reporting</a> that turnout in Georgia is on track to surpass 2020, and The Hill <a href="https://thehill.com/homenews/campaign/4973132-michigan-on-pace-to-break-voter-turnout-records-official-says/">says</a> that Michigan may break turnout records.
Why It Matters: High turnout in Philadelphia would be good news for Harris, but even a loss in Pennsylvania would not be fatal to Trump if he performs well in other swing states.
Georgia, Michigan and Pennsylvania were all key to Joe Biden&#8216;s victory in 2020.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41728436/trump-vs-harris-2024-election-deadlocked-final-emerson-poll-shows-one-candidate-with-small-edge-">Trump Vs. Harris: 2024 Election Deadlocked, Final Emerson Poll Shows One Candidate With Small Edge Among Independents</a></li>
</ul>
Image: Shutterstock.

High Turnout Reported In Key States, Trump Baselessly Alleges 'Massive CHEATING' In Philadelphia

A new study <a href="https://tandfonline.com/doi/full/10.1080/21507740.2024.2303154">published</a> in AJOB Neuroscience reveals that most Americans are supportive of <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> use, a psychedelic compound derived from "magic mushrooms," in supervised, licensed settings. As PsyPost <a href="https://www.psypost.org/majority-of-americans-support-supervised-use-of-psilocybin-for-mental-health-and-well-being/">reported</a>, this approval, spanning across political lines, underscores public openness to the controlled use of <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psilocybin for mental health treatment</a> and general well-being, despite remaining concerns for policy caution.
Psilocybin, a <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule 1</a> drug in the U.S., has long been classified as having a high potential for abuse with no accepted medical use. However, <a href="https://www.benzinga.com/markets/cannabis/24/10/41216395/could-psilocybin-be-a-game-changer-for-millions-battling-depression-new-study-says-yes">recent clinical studies</a> suggest it may help alleviate symptoms of conditions such as treatment-resistant depression when administered under professional supervision. Unlike many medications, psilocybin is considered non-addictive, and studies have found it may also <a href="https://www.benzinga.com/markets/cannabis/24/09/41004196/psilocybin-found-to-be-as-effective-as-lexapro-in-treating-depression-researchers-say">enhance overall well-being</a> in healthy individuals.
This research aimed to explore public perceptions of psilocybin amid <a href="https://www.benzinga.com/markets/cannabis/24/08/40447902/psychedelics-and-mental-health-fda-stalls-but-states-forge-ahead">recent legislative progress</a>, such as Oregon&#8217;s law <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">allowing its therapeutic use</a>. Researchers surveyed 805 Americans, aged 18 to 92, providing background on psilocybin's effects, origin and legal status before asking about support for nationwide legalization.
<h3 class="wp-block-heading">Mental Health Treatment Vs. Well-Being Enhancement</h3>
Participants were presented with two scenarios involving supervised psilocybin use: one for mental health treatment and the other for personal well-being. A strong 89% of participants supported psilocybin use for mental health treatment, while 85% approved its use for well-being enhancement. Though medical use garnered slightly more support, both scenarios saw broad endorsement.
The results show bipartisan support for supervised psychedelic therapy, with younger and more liberal adults showing stronger approval. Older adults and conservatives were more cautious, while those valuing empathy and care were more supportive of psilocybin use in therapy
<h3 class="wp-block-heading">Navigating Caution Amid The Psychedelic Renaissance</h3>
The study also sheds light on the importance of tempering enthusiasm with scientific rigor. According to the researchers, the growing interest in psychedelics comes with the risk of overhyping benefits. Given the early stage of the field, both over- and understatements of trial results are not uncommon. As they noted, while psilocybin shows significant medical potential and a strong safety profile, current evidence doesn&#8217;t support rash conclusions beyond its use in the right context.
While the findings suggest broad public support for supervised psychedelic use, the study focused only on licensed environments, excluding unsupervised or recreational use. Future research could explore attitudes toward these higher-risk aspects.
<h3 class="wp-block-heading">Building Trust And Policy For The Future</h3>
The study authors stressed the need for trust-building and caution in shaping future policies. "If the field can overcome scientific inaccuracies, pursue rigorous research, and build trust—then psychedelics such as psilocybin may one day be seen as a mainstream means to treat mental illness and possibly also to promote overall well-being," they concluded.
With public support reaching bipartisan levels, the potential for psilocybin to become part of standard mental health care is closer to reality than ever, signaling a transformative shift in mental health treatment in the U.S.
Cover image made with AI

Cannabis

Psychedelics

Americans Favor Psilocybin For Mental Health Treatment, Study Finds

DA Davidson analyst Brian Holland maintains Freshpet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPT#NASDAQ">FRPT</a>) with a Buy and raises the price target from $183 to $189.

FRPT

DA Davidson Maintains Buy on Freshpet, Raises Price Target to $189

Hut 8 Says Its Self-Mining Produced 100 BTC In October, Up From 85 BTC In September; Vega Site Buildout Advancing On Track For Q2 2025 Energization

DA Davidson analyst Michael Shlisky maintains Federal Signal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) with a Neutral and lowers the price target from $94 to $90.

DA Davidson Maintains Neutral on Federal Signal, Lowers Price Target to $90

DA Davidson maintains NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) with a Buy and lowers the price target from $55 to $48.

NSSC

DA Davidson Maintains Buy on NAPCO Security Techs, Lowers Price Target to $48

Emerson and its affiliates currently own 57.4% of the Company's outstanding common shares, based on their most recent Schedule 13D filing dated November 5, 2024.
The Board of Directors of AspenTech will follow an appropriate governance process and carefully review the proposal. No action is required by AspenTech shareholders at this time. &nbsp;

AZPN

Aspen Technology Confirms Receipt Of $240/Share Unsolicited Acquisition Proposal From Emerson; Asks Shareholders Not To Take Any Action Pending Review

DA Davidson analyst Brent Thielman maintains Summit Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUM#NYSE">SUM</a>) with a Neutral and raises the price target from $41 to $47.

DA Davidson Maintains Neutral on Summit Materials, Raises Price Target to $47

Guidance

PAAS

Pan American Silver Reaffirms Its 2024 Operating Outlook For Annual Production, Cash Costs And AISC, And Capital Expenditures

Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.21 by 52.38 percent. This is a 3100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $716.10 million which beat the analyst consensus estimate of $699.01 million by 2.44 percent. This is a 16.19 percent increase over sales of $616.30 million the same period last year.

Earnings

Earnings Beats

Pan American Silver Q3 2024 Adj EPS $0.32 Beats $0.21 Estimate, Sales $716.10M Beat $699.01M Estimate

DA Davidson analyst Kevin Fitzsimmons maintains Origin Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBK#NYSE">OBK</a>) with a Buy and lowers the price target from $41 to $38.

DA Davidson Maintains Buy on Origin Bancorp, Lowers Price Target to $38

DA Davidson analyst Gil Luria maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Neutral and raises the price target from $28 to $47.

PLTR

DA Davidson Maintains Neutral on Palantir Technologies, Raises Price Target to $47

The 2024 U.S. presidential election between Vice President Kamala Harris and former President Donald Trump remains one of the closest in history, raising concerns over whether the U.S. Supreme Court may play a decisive role in <a href="https://www.benzinga.com/topic/2024-election">determining the outcome. </a>
As voters head to the polls, election-related legal battles already hint at the possibility of judicial involvement, The New York Times <a href="https://www.nytimes.com/2024/11/05/us/politics/election-supreme-court.html">reports</a>.
What Happened: Several election cases have reached the Supreme Court in recent weeks, including a decision to allow Virginia's removal of over 1,600 voters from its rolls and rulings affecting candidates and voters in battleground states. 
The court decided against removing Robert F. Kennedy Jr. from ballots in key states and authorized provisional ballots in Pennsylvania, after some mail-in ballots were deemed invalid. These cases showcase the judiciary's cautious approach to electoral involvement, although the court's conservative majority could still play a critical role if a close race sparks significant litigation, according to The New York Times.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41759661/us-election-jitters-meet-interest-rate-cut-assurance-why-feds-powell-may-offer-tr">US Election Jitters Meet Interest-Rate Cut Assurance: Why Fed&#8217;s Powell May Offer Traders A Safe Harbor This Week</a>
The Supreme Court's involvement would hinge on an exceptionally narrow vote margin in a critical state, experts say. Prof. Richard Pildes of New York University told The New York Times that a paper-thin margin in a state like Pennsylvania, with its 19 electoral votes, could increase the likelihood of a court ruling influencing the presidential outcome.
Still, experts are cautious, noting that the Supreme Court generally aims to avoid direct involvement in elections.
Beyond the presidential race, the stakes extend to congressional control. Democrats seek to retain the Senate and flip the House, while Republicans push for gains in both chambers. The outcomes in Senate races, including those in Montana and Ohio, could shift control, particularly if Democratic seats in battleground states like Michigan and <a href="https://www.benzinga.com/general/politics/24/11/41725742/2024-election-stakes-potential-sweeps-split-outcomes-in-congressional-presidential-races">Pennsylvania face Republican challenges.</a> 
Why It Matters: A Supreme Court decision might not only impact the presidency but also influence control over Congress, setting a precedent for election litigation. In a scenario reminiscent of the Bush v. Gore case in 2000, if margins are close enough, legal challenges could escalate to the highest court. 
The potential for either party to control both chambers or split Congress suggests significant implications for the future of U.S. legislation and governance, The New York Times notes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41756372/robinhoods-election-contracts-hit-200-million-trades-on-election-day">Robinhood&#8217;s Election Contracts Hit 200 Million Trades On Election Day</a></li>
</ul>
This article was generated using artificial intelligence and was reviewed by Benzinga editors.
Photo: Shutterstock

Government

Legal

Supreme Court Could Step In If 2024 Election Remains Deadlocked

SMCI

Super Micro Computer CEO Says Don't Expect Negative Allocation From NVIDIA

Super Micro Computer CEO Says He Has An 'Open Mind' About Separating CEO And Chairman Roles

Gerdau Reports Q3 Adjusted EBITDA Of R$3.0B, Up 14.9% Q/Q

Citi's 'Catalyst Watch' list of U.S. stocks for crowding analysis

An announcement from Sana Biotechnology ( ($SANA) ) is now available. Sana Biotechnology, Inc. has undergone a leadership restructure with Steven D...

Sana Biotechnology Announces Leadership and CFO Transition

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenaya Therapeutics (TNYA – Research Report) and San...

Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Sana Biotechnology (SANA)

Sana drops two programs to focus on diabetes, autoimmune diseases

Sana Biotechnology (SANA) announced it will prioritize future development activity for SC291, the company's CD19-directed allogeneic CAR T cell the...

Sana Biotechnology to focus on SC291, suspends SC291 in oncology and SC379

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sana Biotechnology (SANA – Research Report) and In...

Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Integra Lifesciences (IART)

JMP Securities downgraded Sana Biotechnology (SANA) to Market Perform from Outperform without a price target after the company announced a portfoli...

Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities

H.C. Wainwright lowered the firm's price target on Sana Biotechnology (SANA) to $8 from $11 and keeps a Buy rating on the shares. The firm adapted ...

Sana Biotechnology price target lowered to $8 from $11 at H.C. Wainwright

Sana lowered to market perform by JMP over data uncertainty

Sana plunges 19% after discontinuing programs

APLS

ASND

IART

LBTYA

MRVL

SANA

SMMT

TNYA

ULTA

VIRT

XLRE

Health Care

Management

Press Releases

Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer

Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer

Sana Biotechnology to Present at September 2024 Investor Conferences

Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry

Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference

A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore

Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors

Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions

Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025

FHTX

MRNA

OMGA

Annexon

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cargo Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Erasca

89bio

IGM Biosciences

Immunome

LENZ Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Neurogene

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oruka Therapeutics

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Replimune Group

Relay Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Stoke Therapeutics

Tourmaline Bio

Tyra Biosciences

Zenas BioPharma

HC Wainwright & Co.

Citigroup

Morgan Stanley

Goldman Sachs

Sana Biotechnology shares are trading lower after JMP Securities downgraded the stock from Market Outperform to Market Perform. Also, HC Wainwright & Co. lowered its price target from $11 to $8.

Comments

Sana Biotechnology

空売り

Sana Biotechnology (NASDAQ:SANA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル